Katharina Grupp1, Julia Wilking2, Kristina Prien3, Claudia Hube-Magg4, Hüseyin Sirma5, Ronald Simon6, Stefan Steurer7, Lars Budäus8, Alexander Haese9, Jakob Izbicki10, Guido Sauter11, Sarah Minner12, Thorsten Schlomm13, Maria Christina Tsourlakis14. 1. General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: k.grupp@uke.de. 2. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: Julia.Wilking@med.uni-giessen.de. 3. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: k.prien@uke.de. 4. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: c.hube@uke.de. 5. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: h.sirma@uke.de. 6. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: r.simon@uke.de. 7. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: s.steurer@uke.de. 8. Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: budaeus@uke.de. 9. Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: haese@uke.de. 10. General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: izbicki@uke.de. 11. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: g.sauter@uke.de. 12. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: s.minner@uke.de. 13. Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Urology, Section for Translational Prostate Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: tschlomm@uke.de. 14. Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Electronic address: mtsourlakis@uke.de.
Abstract
BACKGROUND: The RNA-binding motif protein 3 (RBM3) has recently been suspected as a prognostic biomarker in several cancers. METHODS: RBM3 expression was analysed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancers. RESULTS: RBM3 expression was more often detectable in malignant compared to benign prostate. RBM3 immunostaining was found in 64% of the interpretable prostate cancers and was considered strong in 25.6%. High RBM3 expression was linked to advanced tumour stage, high Gleason score, positive nodal involvement and positive surgical margin status (p<0.0001 each). There was a remarkable accumulation of strong RBM3 expression in v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) positive prostate cancers and tumours harbouring PTEN deletions (p<0.0001 each). Moreover, RBM3 staining was tightly related to early biochemical recurrence if all tumours or subgroups of ERG negative and ERG positive cancers were analysed (p<0.0001 each). In multivariate analysis, including RBM3 staining, Gleason grade, pT stage, prostate-specific antigen (PSA), surgical margin status, and nodal status, the prognostic impact of RBM3 staining retained statistically significance (p=0.0084). CONCLUSION: Our observations indicate that high RBM3 expression is an independent prognostic marker in prostate cancer. The tight link to ERG activation and PTEN deletions suggest interaction with key molecular pathways in prostate cancer.
BACKGROUND: The RNA-binding motif protein 3 (RBM3) has recently been suspected as a prognostic biomarker in several cancers. METHODS: RBM3 expression was analysed by immunohistochemistry on a tissue microarray containing 11,152 prostate cancers. RESULTS: RBM3 expression was more often detectable in malignant compared to benign prostate. RBM3 immunostaining was found in 64% of the interpretable prostate cancers and was considered strong in 25.6%. High RBM3 expression was linked to advanced tumour stage, high Gleason score, positive nodal involvement and positive surgical margin status (p<0.0001 each). There was a remarkable accumulation of strong RBM3 expression in v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) positive prostate cancers and tumours harbouring PTEN deletions (p<0.0001 each). Moreover, RBM3 staining was tightly related to early biochemical recurrence if all tumours or subgroups of ERG negative and ERG positive cancers were analysed (p<0.0001 each). In multivariate analysis, including RBM3 staining, Gleason grade, pT stage, prostate-specific antigen (PSA), surgical margin status, and nodal status, the prognostic impact of RBM3 staining retained statistically significance (p=0.0084). CONCLUSION: Our observations indicate that high RBM3 expression is an independent prognostic marker in prostate cancer. The tight link to ERG activation and PTEN deletions suggest interaction with key molecular pathways in prostate cancer.
Authors: Neil M Carleton; Guangjing Zhu; M Craig Miller; Christine Davis; Prakash Kulkarni; Robert W Veltri Journal: Cancer Rep (Hoboken) Date: 2020-01-29
Authors: Christoph Burdelski; Laura Borcherding; Martina Kluth; Claudia Hube-Magg; Nathaniel Melling; Ronald Simon; Christina Möller-Koop; Philipp Weigand; Sarah Minner; Alexander Haese; Hans Uwe Michl; Maria Christina Tsourlakis; Frank Jacobsen; Andrea Hinsch; Corinna Wittmer; Patrick Lebok; Stefan Steurer; Jakob R Izbicki; Guido Sauter; Till Krech; Franziska Büscheck; Till Clauditz; Thorsten Schlomm; Waldemar Wilczak Journal: Oncotarget Date: 2017-05-09
Authors: Christoph Burdelski; Aleksandra Matuszewska; Martina Kluth; Christina Koop; Katharina Grupp; Stefan Steurer; Corinna Wittmer; Sarah Minner; Maria Christina Tsourlakis; Guido Sauter; Thorsten Schlomm; Ronald Simon Journal: Microarrays (Basel) Date: 2014-04-17